Travere Therapeutics today announced that the Company will present seven abstracts at the upcoming ERA Congress in Vienna, Austria, in June.

Moderator Sagar Nigwekar, MD, of Massachusetts General Hospital in Boston, is joined by Edgar Lerma, MD, of the University of ...

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (NDA) for sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS).

The aim of the present study was to investigate the expression of alpha-smooth muscle actin (alpha-SM-actin) and proliferating cell nuclear antigen (PCNA) in renal cortex from patients with focal ...

As the years and months pass by, my health, due to my kidney failure, has further deteriorated. I fear that I will not ...

Opening of Japan’s first clinical trial site for ACTION3 triggers the first development milestone payment of ¥400 million ...

Dimerix Limited ( ($AU:DXB) ) has issued an update. Dimerix Limited announced the successful completion of the sixth ...

But in 2016, when Brown was diagnosed with Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease that can cause ...

Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") . Such investors are advised to contact Danielle Peyton ...

for the treatment of focal segmental glomerulosclerosis (FSGS). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026, and has indicated that it is ...

AI is reshaping labs and Clever Culture’s tech is gaining Big Pharma attention as diagnostics and cleanrooms go digital.